OBJECTIVE: Endothelial cell activation is an important mediator of monocyte recruitment to sites of vascular inflammation. We hypothesized that high-affinity dual-ligand microparticles of iron oxide (MPIO), targeted to P-selectin and vascular cell adhesion molecule-1 (PV-MPIO), would identify activated endothelial cells during atherosclerosis progression. METHODS AND RESULTS: In vivo magnetic resonance imaging in apolipoprotein E-deficient mice showed rapid binding of PV-MPIO to the aortic root, which was maximal 30 minutes post-MPIO injection and maintained at 60 minutes. Minimal binding was observed for control IgG-MPIO. Intensely low magnetic resonance signal areas, corresponding to PV-MPIO binding, were detected early (14 weeks), during foam cell formation. Contrast effects increased at 20 weeks during fibrofatty lesion development (P<0.05), but reduced by 30 weeks (P<0.01). Across all lesion severities, magnetic resonance imaging contrast effects correlated with lesion macrophage area quantified by immunohistochemistry (R=0.53; P<0.01). Near-infrared fluorescently labeled PV-MPIO were shown, by flow cytometry, to bind only activated endothelial cells and not to macrophages. Using en face immunofluorescence, we further demonstrate selective PV-MPIO accumulation at atherosclerosis-susceptible sites, with minimal binding to atherosclerosis-spared regions. CONCLUSIONS: This high-affinity leukocyte-mimetic magnetic resonance imaging agent reveals endothelial activation. PV-MPIO demonstrate exceptionally rapid in vivo steady state accumulation, providing conspicuous magnetic resonance contrast effects that can be objectively quantified. In atherosclerosis progression, PV-MPIO tracked closely with the burden and distribution of plaque macrophages, not merely plaque size. On a biocompatible platform, this approach has potential for quantitative magnetic resonance imaging of inflammatory disease activity.
OBJECTIVE: Endothelial cell activation is an important mediator of monocyte recruitment to sites of vascular inflammation. We hypothesized that high-affinity dual-ligand microparticles of iron oxide (MPIO), targeted to P-selectin and vascular cell adhesion molecule-1 (PV-MPIO), would identify activated endothelial cells during atherosclerosis progression. METHODS AND RESULTS: In vivo magnetic resonance imaging in apolipoprotein E-deficient mice showed rapid binding of PV-MPIO to the aortic root, which was maximal 30 minutes post-MPIO injection and maintained at 60 minutes. Minimal binding was observed for control IgG-MPIO. Intensely low magnetic resonance signal areas, corresponding to PV-MPIO binding, were detected early (14 weeks), during foam cell formation. Contrast effects increased at 20 weeks during fibrofatty lesion development (P<0.05), but reduced by 30 weeks (P<0.01). Across all lesion severities, magnetic resonance imaging contrast effects correlated with lesion macrophage area quantified by immunohistochemistry (R=0.53; P<0.01). Near-infrared fluorescently labeled PV-MPIO were shown, by flow cytometry, to bind only activated endothelial cells and not to macrophages. Using en face immunofluorescence, we further demonstrate selective PV-MPIO accumulation at atherosclerosis-susceptible sites, with minimal binding to atherosclerosis-spared regions. CONCLUSIONS: This high-affinity leukocyte-mimetic magnetic resonance imaging agent reveals endothelial activation. PV-MPIO demonstrate exceptionally rapid in vivo steady state accumulation, providing conspicuous magnetic resonance contrast effects that can be objectively quantified. In atherosclerosis progression, PV-MPIO tracked closely with the burden and distribution of plaque macrophages, not merely plaque size. On a biocompatible platform, this approach has potential for quantitative magnetic resonance imaging of inflammatory disease activity.
Authors: Matthias Nahrendorf; Farouc A Jaffer; Kimberly A Kelly; David E Sosnovik; Elena Aikawa; Peter Libby; Ralph Weissleder Journal: Circulation Date: 2006-09-25 Impact factor: 29.690
Authors: Olivia Will; Sanjay Purkayastha; Christopher Chan; Thanos Athanasiou; Ara W Darzi; Wady Gedroyc; Paris P Tekkis Journal: Lancet Oncol Date: 2006-01 Impact factor: 41.316
Authors: Qing Ye; Yijen L Wu; Lesley M Foley; T Kevin Hitchens; Danielle F Eytan; Haval Shirwan; Chien Ho Journal: Circulation Date: 2008-07-08 Impact factor: 29.690
Authors: Andrew Jefferson; Rohan S Wijesurendra; Martina A McAteer; Janet E Digby; Gillian Douglas; Thomas Bannister; Francisco Perez-Balderas; Zsolt Bagi; Alistair C Lindsay; Robin P Choudhury Journal: Atherosclerosis Date: 2011-08-05 Impact factor: 5.162
Authors: Daniel J Sobczynski; Margaret B Fish; Catherine A Fromen; Mariana Carasco-Teja; Rhima M Coleman; Omolola Eniola-Adefeso Journal: Ther Deliv Date: 2015-08-14
Authors: Aurélien Quenault; Sara Martinez de Lizarrondo; Olivier Etard; Maxime Gauberti; Cyrille Orset; Benoît Haelewyn; Helen C Segal; Peter M Rothwell; Denis Vivien; Emmanuel Touzé; Carine Ali Journal: Brain Date: 2016-11-08 Impact factor: 13.501
Authors: Zahi A Fayad; Filip K Swirski; Claudia Calcagno; Clinton S Robbins; Willem Mulder; Jason C Kovacic Journal: J Am Coll Cardiol Date: 2018-10-30 Impact factor: 24.094
Authors: Alkystis Phinikaridou; Marcelo E Andia; Ajay M Shah; René M Botnar Journal: Am J Physiol Heart Circ Physiol Date: 2012-10-12 Impact factor: 4.733
Authors: Umar Sadat; Farouc A Jaffer; Marc A M J van Zandvoort; Stephen J Nicholls; Domenico Ribatti; Jonathan H Gillard Journal: Circulation Date: 2014-08-26 Impact factor: 29.690